Xu Hai, Niu Yale, Hong Weiming, Liu Weixin, Zuo Xiaoxin, Bao Xi, Guo Changming, Lu Yu, Deng Bihua
Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Jiangsu Agri-animal Husbandry Vocational College, Taizhou, 225300, Jiangsu Province, PR China; Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Science, Nanjing, 210014, Jiangsu Province, PR China.
Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Science, Nanjing, 210014, Jiangsu Province, PR China.
Comp Immunol Microbiol Infect Dis. 2020 May 30;71:101499. doi: 10.1016/j.cimid.2020.101499.
There has been an increasing interest in finding new formulations that qualify as vaccine adjuvants, which must be safe, stable, and have the capacity to stimulate a strong immune response. In this study, a basic formulation of a water-in-oil-in-water (W/O/W) adjuvant CV13 was developed, and ginseng stem-leaf saponins (GSLS) were added as an immune booster into oil phase. The physicochemical properties of the adjuvant were tested. Furthermore, the immune activity and the adjuvant effects, as indicated by the foot-and-mouth disease virus (FMDV) antigen were evaluated. The results showed that CV13 was similar in appearance to ISA 206 and could package FMDV antigen into a stable W/O/W emulsion. The FMD vaccine prepared with CV13 alone or CV13 containing GSLS achieved pharmaceutical characteristics comparable to a vaccine prepared with ISA 206, moreover the structural stability of the CV 13 vaccine was found to be better. Mice that were immunized with the FMD vaccine prepared with CV13 containing GSLS presented a significantly higher LPBE antibody titer and splenocyte proliferation rate than those immunized with a vaccine prepared with CV13 alone (p < 0.05). In addition, there was no significant difference between the groups that were immunized with FMD vaccine prepared with CV13 containing GSLS and ISA206 in terms of cellular and humoral immune response. In this paper, CV13 containing GSLS shows excellent immunologic adjuvant effect in mice model, and this new adjuvant may provide a potential choice for FMD vaccine production in the future.
人们对寻找符合疫苗佐剂标准的新配方越来越感兴趣,这些佐剂必须安全、稳定,并具有刺激强烈免疫反应的能力。在本研究中,开发了一种水包油包水(W/O/W)佐剂CV13的基本配方,并将人参茎叶皂苷(GSLS)作为免疫增强剂添加到油相中。测试了该佐剂的物理化学性质。此外,还评估了口蹄疫病毒(FMDV)抗原所显示的免疫活性和佐剂效果。结果表明,CV13的外观与ISA 206相似,并且可以将FMDV抗原包装成稳定的W/O/W乳液。单独使用CV13或含有GSLS的CV13制备的FMD疫苗具有与用ISA 206制备的疫苗相当的药学特性,此外还发现CV 13疫苗的结构稳定性更好。用含有GSLS的CV13制备的FMD疫苗免疫的小鼠,其LPBE抗体滴度和脾细胞增殖率显著高于用单独的CV13制备的疫苗免疫的小鼠(p<0.05)。此外,在用含有GSLS的CV13制备的FMD疫苗免疫的组和用ISA206免疫的组之间,在细胞免疫和体液免疫反应方面没有显著差异。本文中,含有GSLS的CV13在小鼠模型中显示出优异的免疫佐剂效果,这种新型佐剂可能为未来FMD疫苗生产提供一种潜在选择。